Key Takeaways
- The Supreme Court refused to hear drugmakers’ appeals, keeping Medicare’s price‑negotiation program intact.
- Lower courts already dismissed the firms’ Fifth Amendment “takings” claims, which argued forced pricing amounted to uncompensated property seizure. – The negotiated discounts, part of the Inflation Reduction Act, began delivering lower prices to seniors in early 2024, with up to 50 % savings on out‑of‑pocket costs.
- AstraZeneca and other manufacturers warned that continued participation is essentially mandatory, forcing them to sell drugs to Medicare or face a 65 % tax penalty.
- The decision preserves billions in federal savings and paves the way for expanding negotiated pricing to an additional 15 drugs—including blockbuster GLP‑1 agents like Ozempic and Wegovy—starting next year. Supreme Court Declines Review The nation’s highest court issued an order on May 18, 2026, declining to grant certiorari in the suite of lawsuits filed by pharmaceutical manufacturers seeking to block Medicare’s authority to negotiate drug prices. The denial leaves the lower‑court rulings in place, confirming that the negotiated pricing scheme can continue without interruption.
Legal Claims Focus on Constitutional “Taking” Clause
Attorneys for AstraZeneca and co‑defendant companies argued that the program violated the Fifth Amendment by compelling them to accept prices set by the government without just compensation, effectively taking their property. The courts consistently held that participation is optional; because firms can opt out, the statute does not constitute a forced taking.
Volunteerism Questioned as “Coercive Choice”
Despite the legal characterization of “voluntary” participation, the plaintiffs contend that the reality is coercive. If a manufacturer refuses to engage in negotiation, its products become subject to a 65 % excise‑type tax if they are sold to any Medicare beneficiary, effectively forcing the company to accept negotiated terms or surrender access to half the U.S. prescription‑drug market.
Statutory Mechanics of the Inflation Reduction Act
The pricing‑negotiation authority stems from the Inflation Reduction Act of 2022, which empowered Medicare to negotiate prices for a limited set of high‑cost drugs. The first round targeted ten medications—including treatments for cancer, heart disease, autoimmune disorders, and diabetes—allowing the federal government to set prices lower than those previously billed to Medicare Part D enrollees.
Immediate Savings for Seniors Beginning in January 2025, seniors enrolled in Medicare Part D began seeing reduced copayments for those initial ten drugs. An AARP analysis published the following month estimated an average out‑of‑pocket cost reduction of more than 50 % for beneficiaries, translating into substantial savings for millions of retirees.
Expanded Negotiations on the Horizon
The Medicare negotiation program is slated to broaden in 2026 to an additional fifteen drugs, among them the high‑profile GLP‑1 diabetes and obesity treatments Ozempic® and Wegovy®. Like their predecessors, these negotiations will likely produce comparable price cuts, further widening the financial impact on the federal health‑care program.
Economic Implications for Federal Programs
Centers for Medicare & Medicaid Services (CMS) officials reported that the first two negotiation cycles generated savings of several billions of dollars for taxpayers. These funds are being earmarked to support the broader health‑care infrastructure and offset other rising costs within Medicare. Industry Pushback Remains Strong
Pharmaceutical trade groups such as the Pharmaceutical Research and Manufacturers of America (PhRMA) continue to protest the negotiated‑price model, characterizing it as an existential threat to innovation. They argue that the negotiation framework undermines the traditional market dynamics that have historically driven pharmaceutical research and development.
Policy Outlook and Future Litigation
Although the Supreme Court’s denial ends this particular round of judicial review, experts anticipate a cascade of further legal challenges as additional drug classes are drawn into the negotiation pipeline. Companies may explore alternative strategies, such as legislative efforts to repeal or reshape the negotiation authority, or pursue state‑level lawsuits aimed at limiting the program’s reach.
Conclusion: A Turning Point for Medicare Pricing
The Supreme Court’s refusal to intervene marks a pivotal moment for Medicare’s ability to negotiate drug prices, affirming that the program can proceed without constitutional impediment. As negotiated discounts roll out across more medications, seniors can expect continued relief on prescription costs, while the pharmaceutical industry faces heightened pressure to adapt to a new pricing landscape that blends government authority with market participation.